Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models

被引：6

作者：

Borodovsky, Alexandra ^{[1
]}

Wang, Yanjun ^{[1
]}

Ye, Minwei ^{[1
]}

Shaw, Joseph C. ^{[1
]}

Sachsenmeier, Kris ^{[1
]}

Deng, Nanhua ^{[1
]}

Goodwin, Kelly ^{[1
]}

Clarke, James D. ^{[1
]}

Goodwin, Richard ^{[1
]}

Strittmatter, Nicole ^{[1
]}

Hay, Carl ^{[2
]}

Sah, Vasu ^{[1
]}

Deborah, Lawson ^{[1
]}

Reimer, Corinne ^{[1
]}

Congreve, Miles ^{[3
]}

Mason, Jonathan ^{[3
]}

Marshall, Fiona ^{[3
]}

Lyne, Paul ^{[1
]}

Woessner, Richard ^{[1
]}

机构：

[1] AstraZeneca, Boston, MA USA

[2] MedImmune, Gaithersburg, MD USA

[3] Heptares Therapeut, Welwyn Garden City, Herts, England

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-3751

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3751

引用

页数：2

共 50 条

[31] Nintedanib Improves Anti-Tumor Efficacy in Combination with Anti PD-1 in Syngeneic Tumor Models Sensitive and Refractory to IO Inhibition
Hilberg, Frank
Reschke, Markus
Hofmann, Marco
Kraut, Norbert
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S813 - S813
[32] BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Zhu, Hengrui
Bengsch, Fee
Svoronos, Nikolaos
Rutkowski, Melanie R.
Bitler, Benjamin G.
Allegrezza, Michael J.
Yokoyama, Yuhki
Kossenkov, Andrew V.
Bradner, James E.
Conejo-Garcia, Jose R.
Zhang, Rugang
CELL REPORTS, 2016, 16 (11): : 2829 - 2837
[33] Mechanical destruction using a minimally invasive Ultrasound Needle induces anti-tumor immune responses and synergizes with the anti-PD-L1 blockade
Tang, Jiawei
Tang, Junhui
Li, Hui
Zhou, Jing
Tang, Najiao
Zhu, Qiong
Wang, Xinxin
Zhu, Bo
Li, Ningshan
Liu, Zheng
CANCER LETTERS, 2023, 554
[34] Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
Maohua Li
Rongqing Zhao
Jianxin Chen
Wenzhi Tian
Chenxi Xia
Xudong Liu
Yingzi Li
Song Li
Hunter Sun
Tong Shen
Wenlin Ren
Le Sun
Scientific Reports, 12
[35] Radiation Therapy Induces an Adaptive Upregulation of PD-L1 on Tumor Cells Which May Limit the Efficacy of the Anti-Tumor Immune Response But Can Be Circumvented by Anti-PD-L1
Illidge, T.
Lipowska-Bhalla, G.
Cheadle, E.
Honeychurch, J.
Poon, E.
Morrow, M.
Stewart, R.
Wilkinson, R.
Dovedi, S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S776 - S776
[36] AZD0171 (anti-LIF) combines productively with chemotherapy and anti-PD-L1 in mouse models of cancer
Candido, Juliana
Kar, Gozde
Zhang, Bairu
Opoku-Ansah, Grace
Grover, Amit
Kuczynski, Elizabeth A.
Slidel, Tim
Palmer, Doug
Wilkinsom, Robert W.
Luheshi, Nadia
Eyles, Jim
CANCER RESEARCH, 2022, 82 (12)
[37] Evaluation of anti-PD-L1 and anti-VEGF-A combinatorial immunotherapy in preclinical murine liver cancer models
Kam, Shing
Ramadori, Pierluigi
Fan, Chaofan
Sagar, Sagar
Heikenwalder, Mathias
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
[38] Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity
Ray, Arghya
Du, Ting
Nupponen, Nina N.
Lehmann, Fredrik
Lindberg, Jakob
Gullbo, Joachim
Richardson, Paul G.
Chauhan, Dharminder
Anderson, Kenneth C.
BLOOD, 2021, 138
[39] Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment
Umezu, Daisuke
Okada, Nana
Sakoda, Yukimi
Adachi, Keishi
Ojima, Toshiyasu
Yamaue, Hiroki
Eto, Masatoshi
Tamada, Koji
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (02) : 201 - 211
[40] Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment
Daisuke Umezu
Nana Okada
Yukimi Sakoda
Keishi Adachi
Toshiyasu Ojima
Hiroki Yamaue
Masatoshi Eto
Koji Tamada
Cancer Immunology, Immunotherapy, 2019, 68 : 201 - 211

← 1 2 3 4 5 →